Pharma Mar Beheer

Beheer criteriumcontroles 1/4

De CEO Pharma Mar is Jose Fernandez Sousa-Faro, benoemd in Jan1986, heeft een ambtstermijn van 38.83 jaar. bezit rechtstreeks 6.35% van de aandelen van het bedrijf, ter waarde € 86.07M. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 9.8 jaar en 2.4 jaar.

Belangrijke informatie

Jose Fernandez Sousa-Faro

Algemeen directeur

n/a

Totale compensatie

Percentage CEO-salaris	n/a
Dienstverband CEO	38.8yrs
Eigendom CEO	6.4%
Management gemiddelde ambtstermijn	9.8yrs
Gemiddelde ambtstermijn bestuur	2.4yrs

Recente managementupdates

Recent updates

Pharma Mar, S.A.'s (BME:PHM) Price Is Right But Growth Is Lacking After Shares Rocket 55%

Oct 16

Pharma Mar, S.A.'s (BME:PHM) Share Price Boosted 27% But Its Business Prospects Need A Lift Too

Jul 28

Pharma Mar (BME:PHM) Will Pay A Larger Dividend Than Last Year At €0.65

Jun 01

Pharma Mar, S.A.'s (BME:PHM) Shares Bounce 29% But Its Business Still Trails The Industry

May 28

Pharma Mar, S.A. Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now

Mar 03

Here's Why Pharma Mar (BME:PHM) Has A Meaningful Debt Burden

Jan 25

Pharma Mar, S.A. (BME:PHM) Shares Could Be 30% Below Their Intrinsic Value Estimate

Apr 28

We Believe That Pharma Mar's (BME:PHM) Weak Earnings Are A Good Indicator Of Underlying Profitability

Mar 08

An Intrinsic Calculation For Pharma Mar, S.A. (BME:PHM) Suggests It's 21% Undervalued

Sep 27

Does Pharma Mar (BME:PHM) Have A Healthy Balance Sheet?

Jul 15

Growth Investors: Industry Analysts Just Upgraded Their Pharma Mar, S.A. (BME:PHM) Revenue Forecasts By 24%

May 04

Pharma Mar (BME:PHM) Has A Pretty Healthy Balance Sheet

Apr 11

There Is A Reason Pharma Mar, S.A.'s (BME:PHM) Price Is Undemanding

Mar 16

Is Pharma Mar (BME:PHM) Using Too Much Debt?

Jan 09

Pharma Mar (BME:PHM) Seems To Use Debt Quite Sensibly

Sep 08

News Flash: Analysts Just Made A Meaningful Upgrade To Their Pharma Mar, S.A. (BME:PHM) Forecasts

Aug 03

Here's Why I Think Pharma Mar (BME:PHM) Is An Interesting Stock

May 31

Pharma Mar (BME:PHM) Has A Rock Solid Balance Sheet

May 10

Is Pharma Mar, S.A. (BME:PHM) Expensive For A Reason? A Look At Its Intrinsic Value

Apr 08

Announcing: Pharma Mar (BME:PHM) Stock Increased An Energizing 231% In The Last Five Years

Jan 14

Is Pharma Mar (BME:PHM) A Risky Investment?

Nov 19

CEO

Jose Fernandez Sousa-Faro

38.8yrs

Tenure

€294,000

Compensatie

Mr. José María Fernández Sousa-Faro, Ph D., founded Pharma Mar, S.A.U. in 1986. He Founded Noscira, S.A., in 2000.He serves as the Chief Executive Officer and President of Pharma Mar, S.A.U. He serves as...

Leiderschapsteam

Naam	Positie	Tenure	Compensatie	Eigendom
Jose Fernandez Sousa-Faro	Founder	38.8yrs	€294.00k	6.35% € 86.1m
Pedro Fernandez Puentes	Executive Vice-Chairman	no data	€124.00k	geen gegevens
Juan Carretero	Founder	no data	geen gegevens	geen gegevens
María de Francia Caballero	Chief Financial Officer	24.8yrs	geen gegevens	geen gegevens
José Moreno Martinez-Losa	Head of Capital Markets & Investor Relations	9.8yrs	geen gegevens	geen gegevens
Juan Pulido	General Counsel & Secretary of the Board of Directors	5.2yrs	geen gegevens	geen gegevens
Sandra Sanchez	Global Compliance Head	4.5yrs	geen gegevens	geen gegevens
Lara Vadillo	Communication Director	no data	geen gegevens	geen gegevens
Belén Veramendi	Director of Corporate Development	2.8yrs	geen gegevens	geen gegevens
Luis Cuenca	Director of Human Resources & IT	21.3yrs	geen gegevens	geen gegevens
Pascal Besman	Chief Operating Officer of Pharmar U.S.	no data	geen gegevens	geen gegevens
Maria Arce	Global Head of Regulatory Affairs	no data	geen gegevens	geen gegevens

9.8yrs

Gemiddelde duur

Ervaren management: Het managementteam van PHM is doorgewinterd en ervaren (gemiddelde ambtstermijn van 9.8 jaar).

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Jose Fernandez Sousa-Faro	Founder	no data	€294.00k	6.35% € 86.1m
Pedro Fernandez Puentes	Executive Vice-Chairman	no data	€124.00k	geen gegevens
Eduardo Serra Rexach	Independent Other External Director	3.8yrs	€35.00k	geen gegevens
M. Solchaga Catalan	Independent Other External Director	no data	€35.00k	geen gegevens
Montserrat Andrade Detrell	Proprietary Director	no data	€34.00k	5.44% € 73.7m
Blanca Hernandez Rodriguez	Independent Director	5.8yrs	geen gegevens	geen gegevens
Maria Sandra Mera	Representative Proprietary Director	3.9yrs	geen gegevens	geen gegevens
Rosa Maria Alonso	Independent Director	2.4yrs	geen gegevens	geen gegevens
Mariano Rodriguez	Independent Coordinating Director	2.4yrs	geen gegevens	geen gegevens
Emiliano Aller	Independent Director	2.4yrs	geen gegevens	geen gegevens
Fernando Santos	Independent Other External Director	no data	geen gegevens	geen gegevens
Soledad Miranda	Independent Director	1.5yrs	geen gegevens	geen gegevens

2.4yrs

Gemiddelde duur

Ervaren bestuur: De raad van bestuur van PHM wordt niet als ervaren beschouwd (gemiddelde ambtstermijn 2.4 jaar), wat duidt op een nieuw bestuur.

Pharma Mar Beheer

Beheer criteriumcontroles 1/4

Belangrijke informatie

Recente managementupdates

Pharma Mar, S.A., Annual General Meeting, May 31, 2023

High number of new directors

High number of new directors

High number of new directors

Pharma Mar, S.A., Annual General Meeting, Apr 15, 2021

Recent updates

Price target increased by 10% to €71.33

Third quarter 2024 earnings released

Pharma Mar, S.A. to Report Q3, 2024 Results on Oct 29, 2024

Pharmamar Announces Positive and Statistically Significant Overall Survival and Progression-Free Survival Results for Zepzelca® and Atezolizumab Combination in First-Line Maintenance Therapy for Extensive-Stage Small Cell Lung Cancer

Pharma Mar, S.A.'s (BME:PHM) Price Is Right But Growth Is Lacking After Shares Rocket 55%

Price target increased by 17% to €60.33

New major risk - Share price stability

Second quarter 2024 earnings released

Pharma Mar, S.A.'s (BME:PHM) Share Price Boosted 27% But Its Business Prospects Need A Lift Too

Pharma Mar, S.A. to Report First Half, 2024 Results on Jul 30, 2024

Consensus EPS estimates increase by 149%

Pharma Mar Presents Encouraging Results At ASCO for Small Cell Lung Cancer

Pharma Mar (BME:PHM) Will Pay A Larger Dividend Than Last Year At €0.65

Pharma Mar, S.A.'s (BME:PHM) Shares Bounce 29% But Its Business Still Trails The Industry

Consensus EPS estimates fall by 76%

Dividend of €0.53 announced

Consensus EPS estimates fall by 29%

New major risk - Dividend sustainability

Pharma Mar, S.A. Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now

Full year 2023 earnings released: EPS: €0.06 (vs €2.73 in FY 2022)

Consensus EPS estimates fall by 78%

Here's Why Pharma Mar (BME:PHM) Has A Meaningful Debt Burden

Price target decreased by 9.1% to €49.83

Consensus EPS estimates fall by 13%, revenue upgraded

New major risk - Earnings quality

Second quarter 2023 earnings released

Price target decreased by 7.4% to €54.83

Consensus EPS estimates fall by 35%

Price target decreased by 9.7% to €57.17

Consensus EPS estimates fall by 22%

Pharma Mar, S.A., Annual General Meeting, May 31, 2023

Price target decreased by 11% to €61.20

Pharma Mar, S.A. (BME:PHM) Shares Could Be 30% Below Their Intrinsic Value Estimate

Consensus EPS estimates fall by 23%, revenue upgraded

Now 20% undervalued after recent price drop

We Believe That Pharma Mar's (BME:PHM) Weak Earnings Are A Good Indicator Of Underlying Profitability

Consensus revenue estimates fall by 11%

Analyst Forecasts Just Became More Bearish On Pharma Mar, S.A. (BME:PHM)

Full year 2022 earnings: EPS misses analyst expectations

Consensus EPS estimates fall by 21%

Price target decreased by 7.6% to €71.03

Pharma Mar (BME:PHM) Has A Rock Solid Balance Sheet

Consensus EPS estimates fall by 17%, revenue upgraded

Now 20% undervalued

Pharma Mar, S.A.(BME:PHM) dropped from Madrid Ibex 35 Index

Now 20% undervalued

High number of new directors

Consensus forecasts updated

We Think Pharma Mar (BME:PHM) Can Manage Its Debt With Ease

An Intrinsic Calculation For Pharma Mar, S.A. (BME:PHM) Suggests It's 21% Undervalued

Now 21% undervalued after recent price drop

Consensus forecasts updated

Investor sentiment deteriorated over the past week

High number of new directors

Pharma Mar, S.A. to Report Q2, 2022 Results on Jul 27, 2022

Second quarter 2022 earnings released

High number of new directors

Does Pharma Mar (BME:PHM) Have A Healthy Balance Sheet?

Upcoming dividend of €0.53 per share

Investor sentiment deteriorated over the past week

Growth Investors: Industry Analysts Just Upgraded Their Pharma Mar, S.A. (BME:PHM) Revenue Forecasts By 24%

Consensus forecasts updated

Pharma Mar (BME:PHM) Has A Pretty Healthy Balance Sheet

There Is A Reason Pharma Mar, S.A.'s (BME:PHM) Price Is Undemanding

Consensus forecasts updated

Full year 2021 earnings: Revenues exceed analyst expectations

Investor sentiment improved over the past week

Pharma Mar, S.A. to Report Q4, 2021 Results on Feb 28, 2022

Pharma Mar, S.A. Announces Publication of an Article in the Life Science Alliance Journal, Entitled "Pre-Clinical and Randomized Phase I Studies of Plitidepsin in Adults Hospitalized with Covid-19

Investor sentiment improved over the past week